GlassScriptPhysician profile
Deneen C Dicarlo
NPI 1497847198
$15,651.09
in general payments reported to CMS, 2019-2025
28 companies · $2,197 in 2025
The $2,197 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,842 · 2020: $1,659 · 2021: $2,179 · 2022: $2,428 · 2023: $2,693 · 2024: $2,654 · 2025: $2,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,543.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,334.40 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $3,325.10 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Novartis Pharmaceuticals Corporation | $1,631.55 | 2019-2025 | |
| Janssen Biotech, INC. | $1,462.01 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Glaxosmithkline, LLC. | $995.24 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $753.63 | 2021-2025 | Saphnelo |
| Pfizer INC. | $587.24 | 2019-2025 | |
| Radius Health, INC. | $469.26 | 2019-2025 | Tymlos |
| Lilly USA, LLC | $393.98 | 2019-2022 | |
| Genzyme Corporation | $354.94 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $325.09 | 2019-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $321.96 | 2022-2025 | Lupkynis |
| Ucb, INC. | $276.40 | 2019-2025 | Bimzelx |
| Ani Pharmaceuticals, INC. | $261.22 | 2023-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $236.74 | 2020-2023 | Krystexxa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $153.35 | 2023-2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $134.82 | 2021-2022 | |
| Genentech USA, INC. | $130.78 | 2019-2025 | Actemra |
| Mallinckrodt Enterprises LLC | $114.51 | 2019 | |
| Progentec Diagnostics, INC. | $105.31 | 2023 | |
| Janssen Scientific Affairs, LLC | $84.61 | 2019 | |
| Celgene Corporation | $57.46 | 2019 | |
| Pacira Therapeutics, INC. | $33.18 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.93 | 2023 | Spevigo |
| Ultragenyx Pharmaceutical INC. | $22.55 | 2021 | |
| Mallinckrodt Hospital Products INC. | $20.27 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $19.64 | 2021 | |
| Amag Pharmaceuticals, INC. | $17.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deneen Dicarlo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.